NovoCure's Optune Pax Wins CE Mark for Pancreatic Cancer, PANOVA-3 Data Shows Survival Benefit
NVCR sits 58% above its 52-week low of $9.82.
Summary
NovoCure's Optune Pax has received CE Mark approval for locally advanced pancreatic cancer, opening the European market for this indication. The approval is based on the PANOVA-3 trial, which showed a median overall survival benefit of 2.0 months (16.2 vs 14.2 months) in the ITT population. This positive regulatory development follows the company's recent announcement on June 18th of the Phase 3 TRIDENT trial failure for glioblastoma. The CE Mark and demonstrated survival benefit in pancreatic cancer represent a significant commercial opportunity and clinical validation for Optune Pax.
At the time of this announcement, NVCR was trading at $15.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.82 to $18.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.